Table 3.
HiLo‐HF registry | HiLo‐HF pilot RCT | ||||
---|---|---|---|---|---|
All (n = 36) | High SpO2 target (n = 18) | Low SpO2 target (n = 18) | P‐value | ||
NT‐proBNP | |||||
Baseline, pg/mL | — | 14 140.1 (5570.6, 27 806.6) | 15 987.9 (6025.6, 29 785.5) | 10 262.5 (4355.3, 27 223.0) | 0.45a |
72 h, pg/mL | — | 7108.9 (4310.5, 17 007.0) | 6479.7 (4529.5, 12 304.9) | 10 156.8 (4001.8, 17 133.8) | 0.72a |
ΔNT‐proBNP, pg/mL | — | −3971.4 (−11 194.5, −1049.5) | −6963.5 (−13 345.1, −1 253.3) | −2093.1 (−5692.1, −353.5) | 0.46a |
72 h to baseline ratio | — | 0.7 (0.5, 0.8) | 0.7 (0.3, 0.8) | 0.6 (0.5, 0.9) | 0.51b |
Secondary endpoints | |||||
---|---|---|---|---|---|
HiLo‐HF registry (n = 43) | All (n = 39) | High SpO2 target (n = 18) | Low SpO2 target (n = 21) | P‐value | |
VAS | |||||
ΔVAS, mm | 15 (5, 35) | 10 (5, 25) | 10 (5, 25) | 10 (7, 20) | 0.86b |
VAS AUC, mm·h | 5295 (4537, 5983) | 5160 (4380, 5932) | 5160 (4050, 6150) | 5167 (4552, 5703) | 0.73 |
PGA | |||||
ΔPGA, mm | 20 (10, 30) | 10 (0, 20) | 5 (0, 20) | 10 (0, 15) | 0.91b |
PGA AUC, mm·h | 4320 (3360, 5280) | 4620 (3840, 5760) | 4860 (4290, 5775) | 4320 (3795, 5670) | 0.63 |
PEF | |||||
ΔPEF, L/min | 45 (0–80) | 47.5 (20, 75) | 52.5 (20, 90) | 42.5 (25, 67.5) | 0.52b |
PEF AUC, L/min·h | 19 920 (12 795, 24 840) | 16 740 (14 610, 22 110) | 15 660 (12 540, 19 500) | 18 960 (16 080, 24 840) | 0.19 |
Diuretic response | |||||
72 h/baseline weight ratio | 0.96 (0.94, 0.98) | 0.96 (0.94, 0.98) | 0.97 (0.94, 0.98) | 0.96 (0.93, 0.97) | 0.55 |
Note: AUC, area under the curve; HiLo, high‐dose oxygen/low‐dose oxygen; NT‐proBNP, N‐terminal pro‐brain‐type natriuretic peptide; PEF, peak expiratory flow; PGA, patient global assessment; RCT, randomized controlled trial; VAS, visual analogue scale.
P‐value based on comparison of high and low SpO2 groups on logarithmic scale.
Test of difference at 72 h adjusting for baseline applying the analysis of covariance model. Unless described otherwise, median (25th percentile, 75th percentile) are reported.